Kevin Kunzmann

Kevin Kunzmann is the managing editor for HCPLive. Prior to joining parent company MJH Life Sciences in 2017, he worked as a health care and government reporter for The Pocono Record, and as a freelance writer for NJ Advance Media, The Express-Times, The Daily Journal, and more. He graduated from Rowan University with a degree in Journalism in 2015. In his spare time, he enjoys reading, cooking, running his dog, and complaining about the Mets. Follow him on Twitter @NotADoctorKevin or email him at kkunzmann@mjhlifesciences.com.

Biography:  https://www.hcplive.com/about-us

98%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

98%

Examples:

  • Kevin Kunzmann reports on the psychiatric potential of semaglutide without disclosing any potential conflicts of interest or biases.

Conflicts of Interest

98%

Examples:

  • There are no disclosures of conflicts of interest in either article.

Contradictions

75%

Examples:

  • In one article, Kevin Kunzmann states that incretin therapy drug classes of GLP-1 and GIP receptor agonists are proving to be a realistic pathway-targeting agent for chronic diseases including psychiatric ones. However, there is no mention or acknowledgement of any potential contradictions with this statement in the other article.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

GLP-1 Receptor Agonists and Psychiatric Issues: Two Cases of Depression and Suicidal Ideation Linked to Semaglutide

GLP-1 Receptor Agonists and Psychiatric Issues: Two Cases of Depression and Suicidal Ideation Linked to Semaglutide

Broke On: Wednesday, 08 May 2024 Two case studies presented at the American Psychiatric Association annual meeting suggest a potential link between GLP-1 receptor agonists like semaglutide and psychiatric issues, including depression and suicidal ideation. The medication, which acts on the brain to modulate food intake and reward, has been associated with approximately 60 reported cases of suicidal ideation since 2018. Further research is needed to identify specific proteins or enzymes that may exacerbate psychological conditions and contribute to these risks.

Semaglutide and Sotagliflozin Show Promising Results for Type 2 Diabetes Patients

Broke On: Friday, 03 November 2023 The majority of patients did not experience worsening of their diabetic retinopathy (DR) after initiating semaglutide (Ozempic) to treat their type 2 diabetes (T2D). Sotagliflozin, a dual SGLT1 and 2 inhibitor, has been found to provide kidney and heart benefits in patients with type 2 diabetes and chronic kidney disease. Over a median follow-up of 16 months, sotagliflozin reduced the risk of kidney-related complications by 38% and a cardiorenal composite outcome by 23%.